



**RETURN BIDS TO:**

**RETOURNER LES SOUMISSIONS À:**

Drugs, Vaccines and Biologics Division/Division des  
produits pharmaceutiques, biologiques et des vaccins  
sherry.meunier@tpsgc-pwgsc.gc.ca

**SOLICITATION AMENDMENT  
MODIFICATION DE L'INVITATION**

The referenced document is hereby revised; unless otherwise  
indicated, all other terms and conditions of the Solicitation  
remain the same.

Ce document est par la présente révisé; sauf indication contraire,  
les modalités de l'invitation demeurent les mêmes.

**Comments - Commentaires**

**Vendor/Firm Name and Address**

Raison sociale et adresse du  
fournisseur/de l'entrepreneur

**Issuing Office - Bureau de distribution**

Drugs, Vaccines and Biologics Division/Div.des  
produits pharmaceutiques,biologiques et de vaccins  
Terrasses de la Chaudière 5th Floo  
10 Wellington Street  
Gatineau  
Quebec  
K1A 0S5

<b>Title - Sujet</b> Propofol	
<b>Solicitation No. - N° de l'invitation</b> E60PH-20PFOL/A	<b>Amendment No. - N° modif.</b> 002
<b>Client Reference No. - N° de référence du client</b> E60PH-20PFOL	<b>Date</b> 2020-05-15
<b>GETS Reference No. - N° de référence de SEAG</b> PW-\$SPH-876-78662	
<b>File No. - N° de dossier</b> ph876.E60PH-20PFOL	<b>CCC No./N° CCC - FMS No./N° VME</b>
<b>Solicitation Closes - L'invitation prend fin</b> <b>at - à 02:00 PM</b> <b>on - le 2020-05-27</b>	
<b>Time Zone</b> <b>Fuseau horaire</b> Eastern Daylight Saving Time EDT	
<b>F.O.B. - F.A.B.</b> Specified Herein - Précisé dans les présentes <b>Plant-Usine:</b> <input type="checkbox"/> <b>Destination:</b> <input type="checkbox"/> <b>Other-Autre:</b> <input checked="" type="checkbox"/>	
<b>Address Enquiries to: - Adresser toutes questions à:</b> Meunier(ph876), Sherry	<b>Buyer Id - Id de l'acheteur</b> ph876
<b>Telephone No. - N° de téléphone</b> (613) 983-2493 ( )	<b>FAX No. - N° de FAX</b> ( ) -
<b>Destination - of Goods, Services, and Construction:</b> <b>Destination - des biens, services et construction:</b> See herein	

**Instructions: See Herein**

**Instructions: Voir aux présentes**

<b>Delivery Required - Livraison exigée</b>	<b>Delivery Offered - Livraison proposée</b>
<b>Vendor/Firm Name and Address</b> <b>Raison sociale et adresse du fournisseur/de l'entrepreneur</b>	
<b>Telephone No. - N° de téléphone</b> <b>Facsimile No. - N° de télécopieur</b>	
<b>Name and title of person authorized to sign on behalf of Vendor/Firm</b> <b>(type or print)</b> <b>Nom et titre de la personne autorisée à signer au nom du fournisseur/</b> <b>de l'entrepreneur (taper ou écrire en caractères d'imprimerie)</b>	
<b>Signature</b>	<b>Date</b>

## Please delete and replace initial RFI with the following:

### REQUEST FOR INFORMATION (RFI) RE: Supply and Demand of Propofol

The Government of Canada recognizes that Canadians who are ill with COVID-19 need access to safe and effective medicines and treatments. As such, the Government of Canada is actively monitoring the impact of the COVID-19 pandemic on the supply of drugs in Canada.

Through this Request for Information (RFI), Canada is seeking to collect information from companies on availability of propofol. This information will be used to inform the Government's response to the ongoing pandemic.

The priority of the Government of Canada is to ensure that there remains a stable supply of propofol for those patients who require it for treatments as currently approved by Health Canada. Monthly demand for propofol has typically been:

- 230,076 units for 10 mg/mL x 20 mL vial
- 19,473 units for 10 mg/mL x 50 mL vial
- 76,749 units for 10 mg/mL x 100 mL vial

Current demand is reported to be two to three times higher than the typical level. This increase has resulted in reported shortages and Health Canada is working with manufacturers, suppliers and distributors to address those shortages.

This request is a tool to identify additional supply that has not already been earmarked to meet Canada's current needs for propofol. The Government of Canada is interested in procuring up to a twelve-month supply at the elevated demand levels, which would support existing efforts to ensure Canadians have access to the drugs they need. In light of ongoing fluctuations in global and domestic demand, should the Government proceed, an incremental procurement approach would be considered.

**Please Note: If your company is currently working with the Government of Canada to address an existing shortage, we are not looking for information on products already identified to mitigate the shortage. The Government of Canada is also interested in receiving information about acceptable substitute drugs.**

If your company is not currently working with the Government of Canada to address an existing shortage, or if you are working with Health Canada but may have access to additional product, we would welcome information on available propofol or equivalent product. We are looking to ensure this drug is available for Canadians without affecting the supply currently available for the Canadian market through existing distribution channels.

The Government of Canada is aware that there are risks of drug shortages globally due to the pandemic and that the current drug shortages faced by Canada are not unique. As such, many jurisdictions are seeking to access the supply from many of the same sources. The Government of Canada remains committed to working with its international partners on the issue of drug shortages to stabilize global supply chains as quickly as possible.

<b>Supply Questions</b> <i>ONLY additional supply (Not needed to meet current demand or proposed to mitigate a current shortage)</i>	<b>Solution for Injection</b>	<b>Other Dosage Form</b> (please provide specifications)
1. Specify the <u>unit strength</u> , <u>vial size</u> , and <u>pack size</u> (e.g. 2mg tablets, bottles of 100)		
2. The additional quantity available by June 30, 2020.		
3. The additional monthly quantity available July 1, 2020 and beyond.		
4. Estimated unit price (per XXX) of finished product, including to deliver to final destination.		
5. Are you currently supplying this product to the Canadian market?  If yes, answer a-d below.  If no, answer 6a-f below.		
a. Confirm that the quantities identified are in excess to supply that has already been earmarked.		
b. Do you have capacity to increase production of the product (Yes/No)  If yes, please specify possible quantity/ month and anticipated lead time for availability of product once a contract is finalized.  Specify conditions, if any.		
c. Provide details of the market authorization (i.e. DIN(s))		
d. Provide the Drug Establishment License number of the Canadian manufacturer or importer, as the case may be.		
6. If product is not authorized for sale in Canada,  a. Do you currently have a submission with Health Canada?		

<p>If Yes, please specify the type of authorization being sought (e.g. NOC, exceptional importation and sale) and include a submission number, if applicable.</p>		
<p>b. Provide a list of countries in which the product is authorized for sale, if applicable</p> <p>As an attachment, provide the product labelling, if available</p>		
<p>c. Is the product fabricated outside of Canada?</p> <p>If yes, has a Canadian importer been identified? Provide the Drug Establishment License number of the importer, if applicable.</p>		
<p>d. Provide information about the product fabrication building(s) (Country name, Company name, Building address, Drug Establishment License number, if applicable)</p>		
<p>e. Provide information about the product Packing/Labelling Building(s) (Country name, Company name, Building address)</p>		
<p>f. Provide information about the product Testing Building(s) (Country name, Company name, Building address)</p>		

**Please specify any caveats of conditions that would apply to the questions provided above. Additionally, for the inventories (units and API) described above, identify what quantities are currently held domestically and what is contingent on being imported into Canada.**

Note: This is not a bid solicitation. Potential suppliers of any goods or services described in this RFI should not reserve stock or facilities, nor allocate resources, as a result of any information contained in this RFI. Also, the procurement of any goods and services described in this RFI will not necessarily follow this RFI. This RFI is simply intended to solicit feedback from industry with respect to the matters described in this RFI.

Canada will not reimburse any respondent for expenses incurred in responding to this RFI.

Responses are to be submitted electronically only. No written/hard copies will be accepted. You are requested to submit a response by May 27th, 2020. Responses are to be sent by e-mail to [Sherry.Meunier@tpsgc-pwgsc.gc.ca](mailto:Sherry.Meunier@tpsgc-pwgsc.gc.ca).